IRB Number:

08-005098

Trial Status:

Open for Enrollment

Phase: II

Why is this study being done?

This study involves treating patients who have suffered an acute ischemic stroke with the medication donepezil (Aricept ®). The intention is to see if taking donepezil (FDA-approved for the treatment of Alzheimer's Disease) for the first 90 days following a stroke enhances recovery.

Who is Eligible to Participate in the Study?

- Stroke within the last 24 hours
- Age ≥18 years.
- Living in independent or semi-independent living situation before the stroke.
- Fluent in English before the stroke.
- No serious vision or hearing impairments
- No history of Parkinson's, seizures, heart failure, restless leg syndrome or asthma.
- No history of gastrointestinal or genitourinary surgery within 1 month prior to stroke.
- No history of gastrointestinal bleeding.
- No history of peptic ulcer disease.

Minimum Age:

18

What is Involved With this Study?

Patients will begin taking donepezil (Aricept) within 24 hours of their stroke. They will be required to return to Mayo Clinic at 30 days, 60 days, 90 days and 6 months after their stroke. Patients will receive medication refills at the 30- and 60-day visits. During all study visits, any problems with the medication and any new medical conditions will be recorded. Patients will complete neuropsych testing at the 30-day, 60-day and 6-month visit.

How long will the Study run?

4 visits over 6 months

Who can I Contact for Additional Information on this Trial?

Alexa Riche
904-953-7839
richie.alexa@mayo.edu

What is/are the Locations of this Clinical Trial?

• Jacksonville, FL

Last updated: 07/07/2009